Phase 3 Domvanalimab Program Discontinued by Arcus Biosciences Amid 39% Q1 Revenue Drop
RCUS has more than doubled off its 52-week low of $7.06.
Summary
Arcus Biosciences reported a significant 39.3% year-over-year decline in first-quarter revenue to $17 million, alongside a net loss of $128 million. More critically, the company announced the discontinuation of the STAR-121 Phase 3 program for its TIGIT inhibitor, domvanalimab, shifting its pipeline focus. This move, while streamlining R&D, represents a material setback for a late-stage asset, following previous clinical setbacks mentioned in the last 10-K. The company is now prioritizing its HIF-2α inhibitor, casdatifan, advancing it into later-stage/Phase 3 development. Despite the revenue miss and program discontinuation, the company maintains a cash runway through at least the second half of 2028. Traders will closely monitor the progress of casdatifan and the impact of reduced R&D expenses on future profitability.
At the time of this announcement, RCUS was trading at $26.06 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.3B. The 52-week trading range was $7.06 to $28.72. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.